Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SYMFI safely and effectively. See full prescribing information for SYMFI. SYMFI® (efavirenz, lamivudine and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
SYMFI® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
- generic_name
- efavirenz, lamivudine and tenofovir disoproxil fumarate
- product_names
- Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
- ndc
- 49502-475, 49502-475-93, 49502-475-77
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en